Results Highlighted in BioProcess International and the Global Bioprocessing and Bioanalytics Congress 2018
JUPITER, FL – June 18, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, discussed its improvements to productivity of its mAb yield using the C1 platform in an article published by BioProcess International and at the Global Bioprocessing and Bioanalytics Congress 2018.
In the BioProcess International article Dyadic CEO Mark Emalfarb discussed the company’s research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies (mAbs), biosimilars and/or biobetters, and other therapeutic proteins.
Between January 2018 and May 2018, Dyadic has improved the productivity of mAb yield using the C1 platform from 1.34 to 2.46 grams per liter per day, an increase of 84 percent. Dyadic reached 9 grams per liter of the target mAb in only 90 hours with 50 percent of the total protein produced as the target mAb. This was accompanied by a 67 percent decrease in media cost. These improvements were conducted by one of Dyadic’s contract research organizations. These results were presented by Dr. Ronen Tchelet, Dyadic’s Vice President of Research & Development, at the Global Bioprocessing and Bioanalytics Congress 2018 in Prague on May 24-25. To view Dr. Tchelet’s presentation, please visit the following link: https://www.dyadic.com/wp-content/uploads/2018/01/C1-Technology-Bioprocessing-Prague-May-24-2018.pdf .
“Dyadic was able to achieve what we believe are record results in a relatively short time by identifying low-cost chemically defined media and applying proprietary optimization and process development to demonstrate record levels of monoclonal antibody productivity,” Mr. Emalfarb said. “We are continuing our R&D efforts and working with partners to further develop our C1 gene expression platform to become the platform of choice for manufacturing protein-based biologics because of speed of development and low cost of goods. The first wave of biologics that we hope to develop are non-glycosylated Fab proteins, followed by glycoproteins, and we expect to update our stakeholders on the timing of these milestones.”
To read the BioProcess International article, please visit the following link: http://www.bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/dyadic-developing-biosimilars-using-cho-challenging-expression-tech/. The article at this link is provided for informational purposes only. Dyadic is not responsible for the content of the linked article.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars/biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.
Please visit Dyadic’s website at http://www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company’s annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at http://www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key customers and collaborators; and (8) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in our December 31, 2017 Annual Report filed with the OTC Markets on March 27, 2018, and our March 31, 2017 Quarterly Report filed with the OTC Markets on May 10, 2018. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.
Dyadic International, Inc.
Ping W. Rawson
Chief Accounting Officer
Phone: +1 (561) 743-8333